Open Payments

MUNSON MEDICAL CENTER

Type
Teaching hospital
Where
Traverse City, MI
Medicare CCN
230097
Received
$307,106 in 149 records, 2019 ($29,099 general, $278,006 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2019General payment32$29,099
2019Research payment117$278,006

By company

CompanyRecordsAmountYears
Merck Sharp & Dohme LLC15$107,5682019
Abbott Laboratories37$100,6102019
PFIZER INC.1$30,0552019
Boston Scientific Corporation17$21,8552019
BIOVERATIV THERAPEUTICS INC.43$15,0412019
Medtronic MiniMed, Inc.3$11,5752019
Medtronic USA, Inc.1$6,9622019
Tandem Diabetes Care, Inc.22$6,1502019
BioFire Diagnostics, LLC1$2,7422019
Bard Peripheral Vascular, Inc.1$1,2762019
ABIOMED1$7502019
GE HEALTHCARE1$7102019
Bayer Healthcare Pharmaceuticals Inc.2$6772019
W. L. Gore & Associates, Inc.1$5402019
Arrow International, Inc.1$4002019
Siemens Medical Solutions USA, Inc.1$1772019
Saol Therapeutics Inc.1$152019

By nature of payment

NatureRecordsAmount
Research payment117$278,006
Compensation for services other than consulting, including serving as faculty or as a speaker at a v28$25,454
Gift2$2,757
Charitable Contribution2$888

Records

DateCompanyAmountNatureFormProductStudyYear
2019-12-31Siemens Medical Solutions USA, Inc.$177Charitable ContributionIn-kind items and services2019
2019-12-30Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-20Medtronic MiniMed, Inc.$3,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-12-11Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-12-03Abbott Laboratories$150Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-12-02Boston Scientific Corporation$1,350Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-12-02Boston Scientific Corporation$1,198Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-11-23Merck Sharp & Dohme LLC$118Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-11-20Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-11-08BioFire Diagnostics, LLC$2,742GiftIn-kind items and servicesUniversal Power Supply for the Torch (58999-60R) Device, Clinical Diagnostics2019
2019-11-08W. L. Gore & Associates, Inc.$540Research paymentCash or cash equivalentProduct in Development Device, DevicesPost-Market Evaluation of the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface for Treatment of In-Stent Rest2019
2019-10-30Abbott Laboratories$5,717Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-10-30Abbott Laboratories$1,010Research paymentCash or cash equivalentSJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart FailureSJM Brady MRI Post Approval Study2019
2019-10-22Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-21Abbott Laboratories$5,750Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-10-16Abbott Laboratories$5,325Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-10-16Merck Sharp & Dohme LLC$721Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-10-16Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-16Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-10-07Boston Scientific Corporation$450Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-10-03Abbott Laboratories$400Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-09-25Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-09-19Medtronic MiniMed, Inc.$2,100Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-09-16Boston Scientific Corporation$1,332Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-09-16Boston Scientific Corporation$564Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-09-09Merck Sharp & Dohme LLC$717Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-09-05Abbott Laboratories$350Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-09-05Abbott Laboratories$350Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-09-05Saol Therapeutics Inc.$15GiftIn-kind items and servicesLioresal (baclofen) Drug, Severe Spasticity2019
2019-09-03Boston Scientific Corporation$450Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$1,250Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$874Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-26BIOVERATIV THERAPEUTICS INC.$123Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-08-23Merck Sharp & Dohme LLC$46,246Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-08-23Merck Sharp & Dohme LLC$21,652Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-08-21Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-08-21Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-08-15Abbott Laboratories$1,750Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-08-15Abbott Laboratories$1,750Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-08-14Abbott Laboratories$650Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-08-14Abbott Laboratories$150Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-08-13Abbott Laboratories$750Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-08-01Bayer Healthcare Pharmaceuticals Inc.$350Research paymentCash or cash equivalentXofigo Drug, OncologyBay88-8223 Alpharadin Combo with abiraterone in CRPC2019
2019-07-31Abbott Laboratories$4,299Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-07-31Abbott Laboratories$2,700Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-07-31Abbott Laboratories$1,550Research paymentCash or cash equivalentSJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart FailureSJM Brady MRI Post Approval Study2019
2019-07-25Abbott Laboratories$1,000Research paymentCash or cash equivalentAMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart FailureClosure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study2019
2019-07-18Abbott Laboratories$5,500Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-07-18Abbott Laboratories$2,500Research paymentCash or cash equivalentXience Device, Cardiac Arrhythmias and Heart FailureXIENCE SHORT DAPT 28 US2019
2019-07-11Abbott Laboratories$1,000Research paymentCash or cash equivalentAMPLATZER Muscular VSD (MuVSD) Occluder Device, Cardiac Arrhythmias and Heart FailureClosure of Muscular Ventricular Septal Defects with the AMPLATZER Muscular VSD Occluder Post Approval Study2019
2019-07-10Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-07-08Abbott Laboratories$366Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2019
2019-07-02Abbott Laboratories$9,625Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-07-02Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-06-25Medtronic MiniMed, Inc.$5,975Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 670G System Device, Durable Pump2019
2019-06-17PFIZER INC.$30,055Research paymentCash or cash equivalentIBRANCE Drug, ONCOLOGYPOLARIS PALBOCICLIB IN HORMONE RECEPTOR POSITIVE ADVANCED BREAST CANCER A PROSPECTIVE MULTICENTER NONINTERVENTIONAL STUD2019
2019-06-17Merck Sharp & Dohme LLC$213Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-06-14Boston Scientific Corporation$855Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-06-14Boston Scientific Corporation$436Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-06-12Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-06-12Merck Sharp & Dohme LLC$200Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3 Randomized, Placebo controlled Study to Evaluate the Safety and Efficacy of Pemetrexed Platinum Chemotherapy 2019
2019-06-07Abbott Laboratories$1,290Research paymentCash or cash equivalentABSORB Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-06-06Merck Sharp & Dohme LLC$17Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-05-30Merck Sharp & Dohme LLC$3,337Research paymentIn-kind items and servicesKEYTRUDA Biological, ONCOLOGYA Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in2019
2019-05-30GE HEALTHCARE$710Charitable ContributionCash or cash equivalent2019
2019-05-30Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-24Arrow International, Inc.$400Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVPS - ARROW Device, Vascular2019
2019-05-15Abbott Laboratories$1,755Research paymentCash or cash equivalentMultiPoint Pacing Device, Cardiac Arrhythmias and Heart FailureMultiPoint Pacing Post Market Study2019
2019-05-15Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-06Boston Scientific Corporation$1,875Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-05-06Boston Scientific Corporation$1,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$1,200Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01Abbott Laboratories$1,011Research paymentCash or cash equivalentSJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart FailureSJM Brady MRI Post Approval Study2019
2019-05-01Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-01Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-01Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-01Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-05-01BIOVERATIV THERAPEUTICS INC.$175Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYAn Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein 2019
2019-04-24Abbott Laboratories$1,900Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-04-12Bard Peripheral Vascular, Inc.$1,276Research paymentCash or cash equivalentLUTONIX Device, PERIPHERAL VASCULARSAFE-DCB REGISTRY BPV140062019
2019-04-01Abbott Laboratories$8,350Research paymentCash or cash equivalentXience V coronary stent system Device, VascularDAPT study2019
2019-04-01Boston Scientific Corporation$870Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-03-31ABIOMED$750Research paymentCash or cash equivalentImpella Device, Cardiology/Vascular DiseasescVAD Registry2019
2019-03-28Medtronic USA, Inc.$6,962Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentMinimed 630G Device, Durable Pump2019
2019-03-26BIOVERATIV THERAPEUTICS INC.$750Research paymentCash or cash equivalentALPROLIX Drug, HEMATOLOGYStudy to Determine the Safety and Efficacy of rFIXFc in Untreated Males With Severe Hemophilia B2019
2019-03-13Abbott Laboratories$1,150Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2019
2019-03-13Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-03-13Abbott Laboratories$50Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2019
2019-03-07Merck Sharp & Dohme LLC$10,000Research paymentCash or cash equivalentLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-03-06Merck Sharp & Dohme LLC$21,661Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-03-06Abbott Laboratories$1,935Research paymentCash or cash equivalentAbsorb Device, VascularA Clinical Evaluation of Absorb BVS, the Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Subjects2019
2019-03-06Merck Sharp & Dohme LLC$818Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-03-06Merck Sharp & Dohme LLC$545Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-03-01Merck Sharp & Dohme LLC$1,104Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-02-19Boston Scientific Corporation$1,020Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-02-06Abbott Laboratories$2,126Research paymentCash or cash equivalentMultiPoint Pacing Device, Cardiac Arrhythmias and Heart FailureMultiPoint Pacing Post Market Study2019
2019-02-04Boston Scientific Corporation$6,000Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-02-04Boston Scientific Corporation$2,500Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-02-04Boston Scientific Corporation$350Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTAPPRAISE ATP2019
2019-02-04Bayer Healthcare Pharmaceuticals Inc.$327Research paymentCash or cash equivalentXofigo Drug, OncologyBay88-8223 Alpharadin Combo with abiraterone in CRPC2019
2019-01-31Merck Sharp & Dohme LLC$213Research paymentIn-kind items and servicesLENVIMA Drug, ONCOLOGYA Phase 3, randomized, double blind trial of pembrolizumab MK 3475 with or without lenvatinib in participants with treat2019
2019-01-30Abbott Laboratories$5,717Research paymentCash or cash equivalentNanostim Leadless Pacemaker Device, Cardiac Arrhythmias and Heart FailureA safety and effectiveness trial for a leadless pacemaker system2019
2019-01-30Abbott Laboratories$5,144Research paymentCash or cash equivalentSJM Tendril MRI Lead Device, Cardiac Arrhythmias and Heart FailureSJM Brady MRI Post Approval Study2019
2019-01-28Abbott Laboratories$14,450Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2019
2019-01-28Abbott Laboratories$50Research paymentCash or cash equivalentXience V coronary stent system Device, VascularAbbott Vascular / XIENCE2019
2019-01-24Abbott Laboratories$3,000Research paymentCash or cash equivalentMultiPoint Pacing Device, Cardiac Arrhythmias and Heart FailureMOre REsponse on Cardiac Resynchronization Therapy (CRT) with MultiPoint Pacing (MPP)2019
2019-01-22Boston Scientific Corporation$855Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-01-22Boston Scientific Corporation$750Research paymentCash or cash equivalentGENERAL TACHY Device, TACHYLSS OF 4 SITE2019
2019-01-16Abbott Laboratories$37Research paymentCash or cash equivalentCardioMEMS Device, Cardiac Arrhythmias and Heart FailureCardioMEMS HF System Post Approval Study2019
2019-01-09Tandem Diabetes Care, Inc.$250Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019
2019-01-03Tandem Diabetes Care, Inc.$300Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentt-slim insulin pump Device, Endocrinology2019

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Grand Traverse CountyTraverse City city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Traverse City, MI, county Grand Traverse County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Traverse City, MI
County
Grand Traverse County, MI
State
Michigan
Population B0100315,59396,16610,077,761
Population, 2020 census P115,67895,23810,077,331
Median age B0100242.743.540.2
Under 18 B0100116.6%19.4%21.2%
65 and over B0100123.9%22.0%18.6%
Households B110017,19140,2874,076,369
Foreign born B050022.5%2.0%7.2%
Median household income B19013$74,087$81,647$72,875
Median family income B19113$106,362$101,748$93,357
Per capita income B19301$53,432$45,034$40,735
Poverty rate B1700112.3%9.6%13.2%
Unemployment rate B230255.2%3.8%5.7%
Civilian labor force B230258,26750,7875,018,449
Mean commute (minutes) B0801317.220.624.2
Bachelor's degree or higher B1500347.4%40.6%32.4%
Housing units B250018,47947,0034,622,236
Owner-occupied B2500363.7%77.2%73.2%
Renters B2500336.3%22.8%26.8%
Median home value B25077$415,400$339,400$231,600
Median gross rent B25064$995$1,288$1,129
White, not Hispanic B0300287.7%90.5%72.4%
Black B030021.3%0.8%13.1%
Hispanic or Latino B030023.6%3.4%5.9%
Asian B030021.1%0.7%3.4%
American Indian and Alaska Native B030020.2%0.4%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Traverse City, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.